FEATURED ARTICLES
Designing A Pivotal Phase 3 CML Trial Around Physician Choice And Patient Quality Of Life
Enliven CMO Helen Collins, MD, explains how Phase 1 findings helped shape trial design, including a multidrug comparator arm, for the company's chronic myeloid leukemia (CML) trial.
-
Firsthand Findings: How Incannex Is Designing Trials That Support Regulatory Approval
Incannex CEO Joel Latham explains how thoughtful trial design and dose optimization can turn promising data into an approval-ready strategy.
-
Novel Science, Familiar Regulatory Pathways: Inside Tonix's Clinical Development Strategy
Tonix CEO Seth Lederman, MD, explains how the company pairs novel science with proven regulatory paths across fibromyalgia, depression, and Lyme disease.
-
A Window Into Aging: Why Skin Is the First Test For RLS-1496
Rubedo’s Marco Quarta explains how patient selection, controls, biopsies, and biomarkers shaped early RLS-1496 trial protocols.